Comments
Loading...

Theravance Biopharma

TBPHNASDAQ
Logo brought to you by Benzinga Data
$8.27
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$21.00
Lowest Price Target1
$9.00
Consensus Price Target1
$13.00

Theravance Biopharma (NASDAQ:TBPH) Stock, Analyst Ratings, Price Targets, Forecasts

Theravance Biopharma Inc has a consensus price target of $13 based on the ratings of 7 analysts. The high is $21 issued by BTIG on April 12, 2024. The low is $9 issued by TD Cowen on August 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and TD Cowen on September 16, 2024, August 6, 2024, and August 6, 2024, respectively. With an average price target of $13 between HC Wainwright & Co., HC Wainwright & Co., and TD Cowen, there's an implied 57.19% upside for Theravance Biopharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
0
0
0
0
May
1
Aug
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
TD Cowen
Leerink Partners
BTIG
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Theravance Biopharma

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Theravance Biopharma (TBPH) stock?

A

The latest price target for Theravance Biopharma (NASDAQ:TBPH) was reported by HC Wainwright & Co. on September 16, 2024. The analyst firm set a price target for $15.00 expecting TBPH to rise to within 12 months (a possible 81.38% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Theravance Biopharma (TBPH)?

A

The latest analyst rating for Theravance Biopharma (NASDAQ:TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.

Q

When was the last upgrade for Theravance Biopharma (TBPH)?

A

The last upgrade for Theravance Biopharma Inc happened on November 5, 2021 when JP Morgan raised their price target to $12. JP Morgan previously had an underweight for Theravance Biopharma Inc.

Q

When was the last downgrade for Theravance Biopharma (TBPH)?

A

The last downgrade for Theravance Biopharma Inc happened on August 6, 2024 when Leerink Partners changed their price target from $15 to $10 for Theravance Biopharma Inc.

Q

When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

Q

Is the Analyst Rating Theravance Biopharma (TBPH) correct?

A

While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $15.00 to $15.00. The current price Theravance Biopharma (TBPH) is trading at is $8.27, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch